Eco Animal Health Group PLC Risk Profile Demonstrated for ECOVAXXIN MS

RNS Number : 4276N

Eco Animal Health Group PLC

08 May 2024

 

8 May 2024

 

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

ECO Animal Health Mycoplasma synoviae vaccine for poultry, ECOVAXXIN^® MS demonstrates favourable risk profile

-     Favourable internal risk assessment reviewed by the United States Department of Agriculture is key to US approval

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that ECOVAXXIN^® MS, its new live vaccine against Mycoplasma synoviae in poultry, is a step closer to approval by the United States Department of Agriculture (USDA) after internal risk assessments demonstrated that the vaccine does not revert to virulence.

Mycoplasma synoviae is a bacterium that can cause respiratory disease and synovitis in chickens and may have deleterious effects on egg production.

Demonstrating that a vaccine strain does not regain virulence after passages through poultry is part of the risk assessment required to obtain a license for the vaccine in the US. These data demonstrating a lack of reversion to virulence have been reviewed by the USDA, which found the study methodology and data acceptable to support the safety of the vaccine strain. 

The vaccine project is the result of a collaboration between ECO and Professor Naola Ferguson-Noel of the Poultry Diagnostic & Research Center, College of Veterinary Medicine at the University of Georgia (UGA), USA. The vaccine strain is a non-pathogenic Mycoplasma synoviae isolate and has been shown previously to be free of antimicrobial resistance (AMR) genes - a prerequisite for US registration.

ECO is working in close collaboration with the USDA for the licensure of its vaccine against Mycoplasma synoviae and to gain authorization to import and distribute the product in the US.

ECO is targeting a launch of ECOVAXXIN^®MS in the US from late 2025.

David Hallas, CEO of ECO, commented: "ECO is focused on building a robust and long-lasting R&D pipeline, and providing the poultry industry with a safe and effective new vaccine against Mycoplasma synoviae is a key element of this. ECOVAXXIN^® MS is the first step in strengthening ECO's ambition to launch multiple vaccine products in key territories." 

"This risk assessment demonstrates that ECO can meet the robust safety threshold set out by the USDA and shows that we are taking the right steps towards obtaining a critical US license."

-Ends-

For further information please contact:

 

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) 020 8447 8899   Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher 020 7496 3000 Investec (Joint Broker) Gary Clarence Lydia Zychowska 020 7597 5970     Equity Development Hannah Crowe Matt Evans 020 7065 2692 ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson 020 3709 5700 [e-mail]

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCQKOBNCBKKQPK